CARRARA TREATMENT / ADDICTION EXPERTS
GLP-1 receptor agonists — a class of medications originally developed for type 2 diabetes that mimic the glucagon-like peptide-1 hormone — are emerging as a significant area of interest in addiction medicine, with early clinical observations suggesting they may dampen the dopamine-driven craving cycle underlying substance use disorders. In this episode of We’re Out of Time, Richard Taite sits down with Dr. Kenneth Spielvogel, Senior Medical Officer at Carrara Treatment, Wellness & Spa, to explore how these medications interact with the brain’s reward pathways and what that could mean for individuals in recovery.
Dr. Spielvogel brings nearly 30 years of medical experience to the conversation. Board-certified in obstetrics and gynecology, he has spent the past several years immersed in addiction medicine, metabolic health, and hormone therapy at Carrara, where he has been directly involved in integrating GLP-1 protocols into clinical treatment plans. His perspective draws on both rigorous medical training — including faculty appointments at UC Irvine and recognition through multiple research awards — and hands-on observation of how these medications perform in a residential treatment setting.
The discussion covers the neurobiological mechanism behind GLP-1 medications, the critical difference between medically supervised use and the growing trend of unsupervised online prescriptions, and why pharmacological intervention alone is insufficient without therapeutic and behavioral support. Dr. Spielvogel also addresses muscle-loss risks, dosing considerations, and the broader implications of GLP-1 research for conditions ranging from cardiovascular disease to neurodegenerative disorders.
GLP-1 receptor agonists such as tirzepatide and semaglutide appear to modulate the dopamine pathway that drives addictive behavior. Dr. Kenneth Spielvogel explains that these medications act on the ventral tegmental area (VTA), which sends dopamine signals through the nucleus accumbens and into the frontal cortex — the circuit responsible for craving and compulsive substance seeking. According to Dr. Spielvogel, GLP-1 medications “squash and temper” the dopamine response in this pathway, reducing the neurological reward signal that reinforces drug and alcohol use. He notes that tirzepatide, a dual GLP-1/GIP receptor agonist, appears to reset the dopamine system faster than natural recovery timelines based on his clinical observations at Carrara. Semaglutide, by contrast, activates only the GLP-1 receptor. This dampening effect does not eliminate pleasure entirely but may meaningfully reduce the outsized reward signal that keeps individuals locked in destructive cycles of substance use.
Dr. Kenneth Spielvogel describes GLP-1 receptor agonists as the most promising pharmacological tool he has encountered in addiction treatment — a stronger endorsement than he gives to naltrexone, Vivitrol, or any prior medication in the field. Part of what distinguishes GLP-1 medications is the breadth of their observed effects: beyond targeting cravings, they appear to address multiple life-threatening conditions simultaneously, including cardiovascular disease, metabolic disorders, and potentially neurodegenerative disease. Dr. Spielvogel also emphasizes that off-label use of medications is an established and widely accepted practice in medicine, citing baby aspirin for cardiovascular prevention and indomethacin for preterm labor as well-known precedents. Carrara began incorporating GLP-1 protocols into its addiction treatment programming approximately two years before any other residential treatment center, according to Dr. Spielvogel, who notes that clinical practice in the addiction field is typically many years behind the available science and research.
Proper dosing and ongoing monitoring are essential with GLP-1 medications, and Dr. Kenneth Spielvogel warns against the growing trend of online prescribers who approve these drugs with minimal clinical evaluation. He recommends starting tirzepatide at 2.5 milligrams rather than the standard 5-milligram starting dose, then adjusting based on individual response and tolerance over time. One of the primary clinical concerns Dr. Spielvogel raises is muscle loss. Without a structured exercise regimen, adequate protein intake, creatine supplementation of 10 to 15 grams daily, and amino acid support, individuals risk losing considerably more muscle mass than fat. The resulting yo-yo cycle — losing weight through muscle depletion then regaining predominantly fat — creates a worse metabolic profile than the starting point. Medical supervision ensures that dosing, nutrition, body composition, and overall health markers are tracked consistently throughout the course of treatment, reducing the risk of serious adverse outcomes.
Dr. Kenneth Spielvogel is direct on this point: pharmacological intervention alone is not sufficient for sustained recovery. While GLP-1 medications may reduce the neurochemical noise of cravings, the underlying psychological and behavioral drivers of addiction remain unaddressed without dedicated therapeutic work. Dr. Spielvogel frames the medication as a tool that quiets the compulsive signal, giving individuals the cognitive and emotional space to engage meaningfully in therapy, process trauma, and develop sustainable coping strategies. The risk of relying solely on medication is significant. If individuals stop taking GLP-1 medications without having built a solid foundation of behavioral change, the craving signals return and relapse becomes highly likely. Carrara’s approach integrates GLP-1 protocols within a broader clinical framework that includes individual therapy, group work, physical fitness programming, nutritional support, and ongoing medical monitoring to address the full spectrum of recovery needs.
The intersection of GLP-1 receptor agonists and substance use disorders represents one of the most actively studied frontiers in addiction medicine. While these medications — including semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro and Zepbound) — received FDA approval for type 2 diabetes and obesity management, a growing body of preclinical and observational evidence suggests their potential application extends to the treatment of addictive disorders.
Research from the National Institute on Drug Abuse (NIDA) has highlighted GLP-1 receptor agonists as a promising area of investigation for substance use disorders. Preclinical studies in animal models have demonstrated that GLP-1 receptor activation can reduce alcohol consumption, decrease cocaine self-administration, and attenuate nicotine-seeking behavior. A 2023 retrospective analysis published in Addiction examining electronic health records of over 80,000 individuals with obesity found that those prescribed semaglutide had significantly lower rates of alcohol use disorder diagnoses compared to matched controls on other anti-obesity medications. While retrospective data cannot establish causation, these findings have accelerated interest in prospective clinical trials.
The mechanism under investigation centers on the mesolimbic dopamine pathway — the same neural circuit discussed by Dr. Spielvogel in this episode. GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens, regions critical to reward processing. By modulating dopamine signaling in these areas, GLP-1 medications may reduce the reinforcing properties of substances without producing the aversive effects associated with some existing medication-assisted treatment approaches.
Current FDA-approved pharmacotherapies for addiction remain limited. Naltrexone and acamprosate address alcohol use disorder; methadone, buprenorphine, and naltrexone target opioid use disorder; and nicotine replacement therapies address tobacco dependence. No single medication spans multiple substance categories. The potential for GLP-1 receptor agonists to reduce craving across several substance types simultaneously distinguishes them from existing options and has drawn attention from both clinical researchers and treatment providers.
At Carrara Treatment, Wellness & Spa, GLP-1 protocols are administered within a comprehensive holistic treatment framework that includes individual and group therapy, fitness programming, nutritional planning, and medical monitoring. This integrated approach reflects the clinical consensus that pharmacological intervention is most effective when combined with behavioral and psychosocial support. Individuals considering GLP-1 medications as part of a recovery plan should work with a qualified medical team experienced in both addiction medicine and metabolic health.
MD - Senior Medical Officer
Carrara Treatment, Wellness & Spa
Dr. Kenneth Spielvogel serves as Senior Medical Officer at Carrara Treatment, Wellness & Spa, where he oversees medical programming that integrates addiction medicine, metabolic health, and hormone therapy into residential treatment. Board-certified by the American Board of Obstetrics & Gynecology, Dr. Spielvogel earned his medical degree from George Washington University School of Medicine and completed his residency at the University of Colorado Health Sciences Center. With nearly 30 years of clinical experience, Dr. Spielvogel has held positions with MemorialCare Medical Group Long Beach, served as clinical faculty in the OB/GYN residency program at UC Irvine, and worked with Pediatrix Medical Group and One Method Treatment Centers. His academic career includes the Dodek Prize for Infertility Research, the E. Stewart Taylor Award for Outstanding Resident Research in Reproductive Sciences, and the Chief Award for Outstanding Teaching Resident (2001). He is fluent in Spanish. Dr. Spielvogel's media contributions include features in Authority Magazine and commentary on the Matthew Perry case in TheBlast. He has published over 20 articles on the Carrara Treatment blog. His current clinical focus centers on GLP-1 receptor agonists in addiction treatment, testosterone and hormone replacement therapy, and the integration of metabolic health protocols into recovery programming.
CONFIDENTIAL CONSULTATION
Take the First Step
Carrara Treatment, Wellness & Spa offers personalized care. Consult a clinician to explore your options.
(888) 383-5207Contact UsFEATURED GUEST
Dr. Kenneth Spielvogel
MD
Dr. Daniel Siegel, founder of interpersonal neurobiology, explains how integration — connecting the differentiated parts of the mind, brain, and relationships — is the foundation of mental health, recovery, and human well-being.
Dr. Daniel Amen, founder of Amen Clinics, explains the neuroscience behind depression, dopamine depletion, chronic pain, and addiction recovery — and why brain health is the missing piece in most treatment programs.
Dr. Timothy Fong, MD explains why co-occurring disorders require integrated treatment, introduces the four domains of recovery, and reframes suicidality as lethal emotional pain.
Dr. Kenneth Spielvogel, MD explains how GLP-1 receptor agonists dampen the dopamine craving cycle in addiction and why medical supervision is essential.
Dr. Bruce Perry, MD, PhD explains how childhood trauma alters the developing brain, the neuroscience of addiction, and evidence-based paths to healing.
Carrara Treatment, Wellness & Spa offers personalized care. Consult a clinician to explore your options.
